A short and cost-effective synthetic route towards antiviral drug Molnupiravir (EIDD-2801) from D-ribose

Molnupiravir

  • Advantages :
    • Starting from basic staring material, D-ribose
    • Indigenous raw materials
    • Scalable process
    • High-yielding steps
    • Overall yield is 32%.
    • No enzymatic steps involved
    • Minimum column purification
  • Commerical Status : Already Commercialised
  • Technology Readiness Level : Technology Development Industrial Application : Process
  • Research Area :Chemical Sciences & Technology Division (CSTD)
  • Description :The prior art towards this API started from an advanced intermediate, and we have developed a process which starts from the basic starting material.